Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Daratumumab,2L SC + 4L IV - Multiple Myeloma relapsed or refractory,Daratumumab,Options for investment,,
